Laboratory-Treated Donor Natural Killer Cells and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Recurrent and/or Metastatic Ovarian Cancer - Related Studies

Laboratory-Treated Donor Natural Killer Cells and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Recurrent and/or Metastatic Ovarian Cancer

This study is currently recruiting participants.

Study NCT00652899. Last updated on October 25, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Ovarian Cancer

2	Additional conditions recognized in this trial
		Ovarian Neoplasms

3	More general conditions related to this trial
		Adnexal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Neoplasms
		Neoplasms by Site
		Ovarian Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		aldesleukin
		cyclophosphamide
		fludarabine phosphate
		lymphokine-activated killer cells
		therapeutic allogeneic lymphocytes

5	Additional drug interventions recognized in this trial
		Fludarabine
		Fludarabine monophosphate

6	More general drug interventions related to this trial
		Alkylating Agents
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antirheumatic Agents
		Antiviral Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Masonic Cancer Center, University of Minnesota
		National Cancer Institute (NCI)